Sorry, you need to enable JavaScript to visit this website.

DAURISMO™ (glasdegib) Dosage and Administration

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose and Schedule

The recommended dose of DAURISMO is 100 mg orally once daily on days 1 to 28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control. For patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response.

Administer DAURISMO with or without food. Do not split or crush DAURISMO tablets. Administer DAURISMO about the same time each day. If a dose of DAURISMO is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of DAURISMO is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses of DAURISMO within 12 hours.

2.2 Monitoring and Dose Modifications

Assess complete blood counts, electrolytes, renal, and hepatic function prior to the initiation of DAURISMO and at least once weekly for the first month. Monitor electrolytes and renal function once monthly for the duration of therapy. Obtain serum creatine kinase levels prior to initiating DAURISMO and as indicated clinically thereafter (e.g., if muscle symptoms are reported). Monitor electrocardiograms (ECGs) prior to the initiation of DAURISMO, approximately one week after initiation, and then once monthly for the next two months to assess for QTc prolongation. Repeat ECG if abnormal. Certain patients may require more frequent and ongoing ECG monitoring [see Warnings and Precautions (5.2)]. Manage any abnormalities promptly [see Adverse Reactions (6.1)].

See Table 1 for dose modification guidelines for patients who develop an adverse reaction.

Table 1. Recommended Dose Modifications for Adverse Reactions
Adverse Reaction Recommended Action
*
Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening.
QTc interval prolongation on at least 2 separate electrocardiograms (ECGs) QTc interval greater than 480 ms to 500 ms Assess electrolyte levels and supplement as clinically indicated.
Review and adjust concomitant medications with known QTc interval-prolonging effects [see Drug Interactions (7)].
Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation to less than or equal to 480 ms.
QTc interval greater than 500 ms Assess electrolyte levels and supplement as clinically indicated.
Review and adjust concomitant medications with known QTc interval-prolonging effects [see Drug Interactions (7)].
Interrupt DAURISMO.
Resume DAURISMO at a reduced dose of 50 mg once daily when QTc interval returns to within 30 ms of baseline or less than or equal to 480 ms.
Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.
Consider re-escalating the dose of DAURISMO to 100 mg daily if an alternative etiology for the QTc prolongation can be identified.
QTc interval prolongation with life-threatening arrhythmia Discontinue DAURISMO permanently.
Hematologic toxicity Platelets less than 10 Gi/L for more than 42 days in the absence of disease Discontinue DAURISMO and low-dose cytarabine permanently.
Neutrophil count less than 0.5 Gi/L for more than 42 days in the absence of disease Discontinue DAURISMO and low-dose cytarabine permanently.
Nonhematologic toxicity Grade 3* Interrupt DAURISMO and/or low-dose cytarabine until symptoms reduce to mild or return to baseline.
Resume DAURISMO at the same dose level, or at a reduced dose of 50 mg.
Resume low-dose cytarabine at the same dose level, or at a reduced dose of 15 mg or 10 mg.
If toxicity recurs, discontinue DAURISMO and low-dose cytarabine.
If toxicity is attributable to DAURISMO only, low-dose cytarabine may be continued.
Grade 4* Discontinue DAURISMO and low-dose cytarabine permanently.

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question on a Pfizer Over-the-Counter Product?
For Pfizer Consumer Healthcare non-prescription or over-the-counter products such as Advil, Centrum, Nexium or Thermacare, call (800) 322-3129
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit www.PfizerRxPathways.com.

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit www.MyPfizerBrands.com for more information.